Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT05573126 | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | recruiting | Phase 1 / Phase 2 | 95 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 |
| NCT04986579 | Scalp Cooling in MBC | recruiting | Phase 2 | 120 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07654257 | Single FrAction Interstitial BreaSt BracHytherApy(SASHA) | not yet recruiting | Phase 2 | 134 | Virginia Commonwealth UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657130 | Optimal Application Timing of ADC Drugs for Advanced Breast Cancer | recruiting | Phase 2 | 120 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07658183 | A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 120 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213041 | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | completed | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04298086 | A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04614194 | Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01730833 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | completed | Phase 2 | 63 | City of Hope Medical CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07597629 | A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer | recruiting | Phase 2 | 36 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure | terminated | Phase 2 | 224 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647016 | Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00929214 | Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT01556243 | Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer | completed | Phase 2 | 270 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05226663 | A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06974929 | A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | recruiting | Phase 1 / Phase 2 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06224673 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | recruiting | Phase 2 | 36 | Laura Huppert, MD, BAOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07102940 | Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer | not yet recruiting | Phase 2 | 50 | George Washington UniversityOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07560475 | Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07618923 | Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer(TD-DASHER-01) | not yet recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07643428 | Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors(CLARA) | not yet recruiting | Phase 2 | 35 | Medical College of WisconsinOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07643584 | De-Escalation of Axillary Management in Advanced Nodal Disease(DEMAND) | not yet recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05558722 | Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer(ACNTBC) | active not recruiting | Phase 2 | 31 | Xijing HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06771609 | Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07198724 | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer(ERADICATE) | recruiting | Phase 1 / Phase 2 | 65 | Kristina A. FanucciOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT06513364 | Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | completed | Phase 2 | 40 | Beijing Wehand-Bio Pharmaceutical Co., LtdINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635342 | Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 182 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02738866 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04529044 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | recruiting | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06214793 | Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) | suspended | Phase 2 | 61 | Megan Kruse, MDOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630103 | Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer | not yet recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 23, 2026source: clinicaltrials